Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study-Reference-Cited by-同舟云学术

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study

Published:2021-11-22 Issue:1 Volume:62 Page:78-88
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache

Author:

Gladstone Jonathan¹,Chhibber Sameer²,Minhas Jagdeep³,Neish Calum S.³,Power G. Sarah³,Lan Zhiyi³,Rochdi Driss⁴^ORCID,Lanthier‐Martel Jessica⁴,Bastien Natacha⁴

Affiliation:

1. Neurology Cleveland Clinic Canada Toronto Ontario Canada

2. Department of Clinical Neurosciences University of Calgary Calgary Alberta Canada

3. Real‐world Solutions IQVIA Kirkland Québec Canada

4. Neuroscience Novartis Pharmaceuticals Canada Inc. Dorval Québec Canada

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.14218

Reference22 articles.

1. Migraine prevalence, diagnosis, and disability;Becker WJ;Can J Neurol Sci,2007

2. Migraine Prevalence, Treatment and Impact: The Canadian Women and Migraine Study

3. Prevalence of Migraine Headache in Canada: A Population-Based Survey

4. A Canadian Population Survey on the Clinical, Epidemiologic and Societal Impact of Migraine and Tension-Type Headache

5. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine;Headache: The Journal of Head and Face Pain;2024-09-13

2. Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study;Headache: The Journal of Head and Face Pain;2024-09-09

3. Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland;Value in Health;2024-08

4. Exploring Erenumab’s Efficacy and Safety for Migraine Prevention in Real-World Settings: A Systematic Review;Cureus;2024-07-28

5. Erenumab escalation in migraine - double dose without additional benefit - a retrospective experience;Acta Neurologica Belgica;2024-07-27